Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).

Tarih
2021
Yazar
Yu, Evan Y.
Alva, Ajjai Shivaram
Csoszi, Tibor
ÖZGÜROĞLU, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Rodriguez-Vida, Alejo
Mamtani, Ronac
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Powles, Thomas
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/174491
https://doi.org/10.1200/jco.2021.39.6_suppl.439
Koleksiyonlar